Pepsi Next introduces cherry vanilla, paradise mango flavors
PURCHASE, N.Y. — Pepsi has expanded its Pepsi Next brand with two new flavors.
Pepsi Next cherry vanilla and Pepsi Next paradise mango flavors deliver real cola taste with 60% less sugar than regular Pepsi, the company said.
"Earlier this spring, Pepsi Next launched to national fanfare, turning cola lovers into believers by delivering on real cola taste with 60% less sugar than Pepsi, and for many, it was love at first sip," Pepsi VP marketing Angelique Krembs said. "We’re continuing the momentum by infusing real cola taste with unique flavor blends, and giving cola lovers two more reasons to drink it to believe it."
Pepsi Next cherry vanilla and Pepsi Next paradise mango flavors will be available at Walmart Supercenter stores nationwide and wherever Pepsi products are sold beginning July 15 through Sept. 8.
NACDS statement to Senate reflects pharmacy’s commitment to patient care, safer communities
ALEXANDRIA, Va. — The National Association of Chain Drug Stores announced on Wednesday that it has submitted a statement to the Senate Caucus on International Narcotics Control, detailing chain pharmacy’s engagement in the prevention of prescription drug abuse, and its commitment to maintaining patients’ ready access to medications vital for pain management and for treatment regimens.
NACDS submitted its statement for the Caucus’ hearing on “Responding to the Prescription Drug Abuse Epidemic.”
"Chain pharmacies have zero tolerance for prescription drug abuse,” NACDS stated. “NACDS and the chain pharmacy industry are committed to partnering with law enforcement agencies, policymakers, and others to work on viable strategies to prevent prescription drug abuse.”
While emphasizing chain pharmacy’s extensive engagement on this issue, NACDS urged, “As we pursue solutions to the problem of prescription drug abuse, it is critical that we do not place undue burdens on legitimate patients who require prescription medications.”
NACDS described chain pharmacy’s proactive role on a daily basis in working to keep communities safe and helping to prevent the human costs of illegal prescription drug use, including the following:
Training of chain pharmacy personnel and the implementation of various company policies and procedures to help prevent diversion and abuse;
Compliance with Drug Enforcement Administration inspections and regulations and Food and Drug Administration regulations;
Frequent dialogue with DEA officials;
Loss prevention and internal security systems;
Participation in state-controlled prescription drug monitoring programs;
Support for FDA’s use of Risk Evaluation and Mitigation Strategies;
Collaboration with the White House Office of National Drug Control Policy and support for public education programs;
Advancement of e-prescribing, including accelerated deployment of e-prescribing of controlled substances;
Support for law-enforcement-authorized programs for the return and disposal of unwanted prescription drugs;
Cooperation with local law enforcement;
Targeting and continued crack-down on illegitimate online drug sellers; and
Support for efforts to shut down rogue pain clinics.
“NACDS and our members are committed to the health and welfare of our patients, as well as all Americans, including ensuring that they do not fall victim to prescription drug abuse. The prescription drug abuse problem can be successfully curbed. However, chain pharmacy cannot solve this problem alone. There must be a holistic approach. All affected stakeholders, including every sector mentioned in this document must work proactively to tackle and resolve this problem. We all must work together at the federal, state, and local levels,” NACDS stated.
FDA approves weight-loss drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a new weight-loss drug made by Vivus, the agency said.
The FDA announced the approval of Qsymia (phentermine and topiramate) extended-release, designed for use by overweight and obese adults alongside a reduced-calorie diet and exercise for chronic weight management. The drug’s original brand name was Qnexa.
"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "Qsymia, used responsibly in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, provides another treatment option for chronic weight management in Americans who are obese or are overweight and have at least one weight-related comorbid condition."